142 related articles for article (PubMed ID: 34404682)
21. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.
Breccia M; Martelli M; Cannella L; Russo E; Finolezzi E; Stefanizzi C; Levi A; Frustaci A; Alimena G
Leuk Res; 2008 Feb; 32(2):353-5. PubMed ID: 17825907
[TBL] [Abstract][Full Text] [Related]
22. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
23. Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.
Mo X; Zhou M; Yan H; Chen X; Wang Y
Cancer Med; 2021 Aug; 10(15):5338-5346. PubMed ID: 34189859
[TBL] [Abstract][Full Text] [Related]
24. US trends in survival disparities among adolescents and young adults with non-Hodgkin lymphoma.
Kent EE; Breen N; Lewis DR; de Moor JS; Smith AW; Seibel NL
Cancer Causes Control; 2015 Aug; 26(8):1153-62. PubMed ID: 26084209
[TBL] [Abstract][Full Text] [Related]
25. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.
Chen Y; Wang H; Kantarjian H; Cortes J
Leuk Lymphoma; 2013 Jul; 54(7):1411-7. PubMed ID: 23121646
[TBL] [Abstract][Full Text] [Related]
26. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
[TBL] [Abstract][Full Text] [Related]
27. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998.
Eltom MA; Jemal A; Mbulaiteye SM; Devesa SS; Biggar RJ
J Natl Cancer Inst; 2002 Aug; 94(16):1204-10. PubMed ID: 12189223
[TBL] [Abstract][Full Text] [Related]
28. Changing incidence of non-Hodgkin lymphomas in the United States.
Clarke CA; Glaser SL
Cancer; 2002 Apr; 94(7):2015-23. PubMed ID: 11932904
[TBL] [Abstract][Full Text] [Related]
29. Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.
Gajendra S; Sharma A; Sharma R; Gupta SK; Sood N; Sachdev R
Turk Patoloji Derg; 2019; 35(1):74-78. PubMed ID: 28272671
[TBL] [Abstract][Full Text] [Related]
30. Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database.
Varterasian ML; Graff JJ; Severson RK; Weiss L; al-Katib AM; Kalemkerian GP
Cancer Invest; 2000; 18(4):303-8. PubMed ID: 10808365
[TBL] [Abstract][Full Text] [Related]
31. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous occurrence of chronic myelogenous leukemia and non-Hodgkin lymphoma at diagnosis.
Acar H; Ecirli S; Gündoğan F; Bulay O; Acar A
Cancer Genet Cytogenet; 1999 Jan; 108(2):171-4. PubMed ID: 9973949
[TBL] [Abstract][Full Text] [Related]
33. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
Gunnarsson N; Sandin F; Höglund M; Stenke L; Björkholm M; Lambe M; Olsson-Strömberg U; Richter J; Själander A
Eur J Haematol; 2016 Oct; 97(4):387-92. PubMed ID: 26833713
[TBL] [Abstract][Full Text] [Related]
34. Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S.
Chihara D; Ito H; Matsuda T; Katanoda K; Shibata A; Saika K; Sobue T; Matsuo K
Oncologist; 2012; 17(12):1547-50. PubMed ID: 22971523
[TBL] [Abstract][Full Text] [Related]
35. Value of survival gains in chronic myeloid leukemia.
Yin W; Penrod JR; Maclean R; Lakdawalla DN; Philipson T
Am J Manag Care; 2012 Nov; 18(11 Suppl):S257-64. PubMed ID: 23327457
[TBL] [Abstract][Full Text] [Related]
36. Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Famenini S; Martires KJ; Zhou H; Xavier MF; Wu JJ
J Am Acad Dermatol; 2015 Jan; 72(1):78-84. PubMed ID: 25440434
[TBL] [Abstract][Full Text] [Related]
37. Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.
Penot A; Preux PM; Le Guyader S; Collignon A; Herry A; Dufour V; Monnereau A; Woronoff AS; Troussard X; Pons E; Bordessoule D; Maynadié M
Leuk Lymphoma; 2015 Jun; 56(6):1771-7. PubMed ID: 25535815
[TBL] [Abstract][Full Text] [Related]
38. The option value of innovative treatments in the context of chronic myeloid leukemia.
Sanchez Y; Penrod JR; Qiu XL; Romley J; Thornton Snider J; Philipson T
Am J Manag Care; 2012 Nov; 18(11 Suppl):S265-71. PubMed ID: 23327458
[TBL] [Abstract][Full Text] [Related]
39. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis.
Menzin J; Lang K; Earle CC; Glendenning A
Drugs Aging; 2004; 21(11):737-46. PubMed ID: 15323579
[TBL] [Abstract][Full Text] [Related]
40. Trends in leukemia incidence and survival in the United States (1973-1998).
Xie Y; Davies SM; Xiang Y; Robison LL; Ross JA
Cancer; 2003 May; 97(9):2229-35. PubMed ID: 12712476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
